Ann: Antisense Therapeutics transitions to new Board Chair, page-102

Again, please refer to the Quarterly Activities Report & Appendix 4C dated 29-07-2021

Manufacture of ATL1102 clinical supplies for Phase IIb trial in DMD
The manufacture of a batch of ATL1102 active pharmaceutical ingredient (API) for the Phase IIb trial was undertaken in North America by Nitto Denko Avecia (Avecia).Upon completion of the manufacture of this batch of API, the material was then shipped to Contract, Parenteral (injectable) Drug Product Manufacturer Pyramid Laboratories (Pyramid) in Costa Messa, Southern California and formulated into injectable product for use in the Phase IIb trial. Importantly, both Avecia and Pyramid have commercial capabilities to support advanced clinical trials and subsequent commercial supply.

So, I would assume the manufacture of the batch API hasn't finished yet...